Smoke, GPx activity and symptoms improvement in patients with drug-naive first-episode schizophrenia: A large-scale 12-week follow-up study. 2022

Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China.

The relationship between tobacco smoke and schizophrenia (SZ) is well established. Smoking is hypothesized to alleviate symptoms and reduce the adverse effects of antipsychotic medications in patients with SZ. However, the underlying biological mechanisms by which smoke improves symptoms in SZ remain unclear. The aim of this study was to investigate the effect of smoking on clinical symptoms and antioxidant enzyme activity after risperidone treatment in a 12-week prospective cohort study of drug-naïve first-episode (DNFE) SZ patients. Two hundred and fifteen DNFE patients were recruited and received 12 weeks of risperidone monotherapy. The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of patient's symptoms at baseline and post-treatment. Plasma GPx activity was also measured at baseline and at the end of 12 weeks. Smokers showed greater improvement in negative symptoms relative to nonsmokers with DNFE SZ. In addition, repeated ANCOVA analysis showed no significant interaction of time and group on GPx activity. Improvement in negative symptoms was not associated with changes in GPx activity. However, in nonsmokers, increased GPx activity was correlated with improvement in positive symptoms.

UI MeSH Term Description Entries
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D012906 Smoke Visible gaseous suspension of carbon and other particulate matter emitted from burning substances.
D012907 Smoking Willful or deliberate act of inhaling and exhaling SMOKE from burning substances or agents held by hand. Smoking Behaviors,Smoking Habit,Behavior, Smoking,Behaviors, Smoking,Habit, Smoking,Habits, Smoking,Smoking Behavior,Smoking Habits
D014028 Tobacco Smoke Pollution Contamination of the air by tobacco smoke. Air Pollution, Tobacco Smoke,Environmental Pollution, Tobacco Smoke,Passive Smoking,Smoking, Passive,Environmental Smoke Pollution, Tobacco,Environmental Tobacco Smoke Pollution,Involuntary Smoking,Second Hand Smoke,Secondhand Smoke,Secondhand Smoking,Hand Smoke, Second,Hand Smokes, Second,Involuntary Smokings,Passive Smokings,Pollution, Tobacco Smoke,Pollutions, Tobacco Smoke,Second Hand Smokes,Secondhand Smokes,Secondhand Smokings,Smoke Pollution, Tobacco,Smoke Pollutions, Tobacco,Smoke, Second Hand,Smoke, Secondhand,Smokes, Second Hand,Smokes, Secondhand,Smoking, Involuntary,Smoking, Secondhand,Smokings, Involuntary,Smokings, Passive,Smokings, Secondhand,Tobacco Smoke Pollutions
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
February 2022, The international journal of neuropsychopharmacology,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
December 2020, Psychoneuroendocrinology,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
November 2021, Psychoneuroendocrinology,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
October 2023, Current neuropharmacology,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
April 2024, Progress in neuro-psychopharmacology & biological psychiatry,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
January 2022, Frontiers in psychiatry,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
September 1999, The American journal of psychiatry,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
March 2023, Asian journal of psychiatry,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
October 1991, Schizophrenia research,
Nan Chen, and Haixia Liu, and Jing Yao, and Song Chen, and Meihong Xiu, and Fengchun Wu, and Xiangyang Zhang
September 2014, Schizophrenia research,
Copied contents to your clipboard!